Abstract
Purpose
To evaluate the performance of the Cutaneous Leishmaniasis Impact Questionnaire (CLIQ) using the EuroQol-5 Dimension (EQ-5D-3L) as a reference standard (criterion validation); to evaluate the responsiveness of the instruments and estimate a cut-off point for the CLIQ to be able to discriminate between high and low impacts of cutaneous leishmaniasis on patients.
Methods
Between 2020 and 2022, a longitudinal validation study was conducted at a reference centre for leishmaniasis in Brazil. The EQ-5D-3L and CLIQ questionnaires were administered before, during and after treatment for cutaneous leishmaniasis. The correlation between the instruments was assessed using Spearman’s correlation coefficient, responsiveness was assessed using the Wilcoxon test, and CLIQ cut-off points were proposed based on results of the EQ-5Q-3L, dichotomized between patients reporting no problems’ and ’some or extreme problems’.
Results
There were satisfactory correlation coefficients between the two instruments before (-0.596) and during treatment (-0.551) and a low correlation between the instruments after the end of treatment (-0.389). In general, the responsiveness of the instruments was satisfactory. The CLIC scores that maximized sensitivity and specificity for recognizing impaired health status before and during treatment were 7 points and 17 points, respectively. However, at the end of treatment, based on the results for the EQ-5D-3L, the CLIC was not able to discriminate between individuals with high and low impacts of the disease.
Conclusion
The CLIQ corresponds well with the EQ-5D-3L when applied before and during treatment but does not seem to be appropriate for follow-up evaluations after the end of treatment.
Funder
Projeto Inovação Fiocruz
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Publisher
Public Library of Science (PLoS)
Reference38 articles.
1. Cutaneous leishmaniasis: recent developments in diagnosis and management;HJC de Vries;Am J Clin Dermatol,2015
2. Complexities of Assessing the Disease Burden Attributable to Leishmaniasis;C Bern;PLoS Negl Trop Dis,2008
3. BRASIL M da SaúdeS de V em SaúdeD de I e DT. TabNet. Leishmaniose Tegumentar Americana: Casos confirmados Notificados no Sistema de Informação de Agravos de Notificação, Brasil. 2022 [cited 2 Oct 2023]. http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinannet/cnv/ltabr.def
4. The psychological impact of cutaneous leishmaniasis;M Yanik;Clin Exp Dermatol,2004
5. Psycho-social impacts, experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and case management: An exploratory qualitative study in Tunisia;A Boukthir;PLoS One,2020